La cadena de opciones muestra datos clave de las opciones de acciones de Tenon Medical a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Tenon Medical..

Tenon Medical (NASDAQ:TNON) Bolsa, Cadena de Opciones

Tenon Medical

Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.

Tenon Medical Inc

Piper Sandler analyst Mark Lear maintains Sitio Royalties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STR#NYSE">STR</a>) with a Overweight and lowers the price target from $28 to $26.

News

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on Sitio Royalties, Lowers Price Target to $26

UBS analyst Damian Karas maintains Crane NXT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXT#NYSE">CXT</a>) with a Neutral and lowers the price target from $62 to $60.

UBS Maintains Neutral on Crane NXT, Lowers Price Target to $60

Piper Sandler analyst Mark Lear maintains Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Neutral and raises the price target from $32 to $40.

Piper Sandler Maintains Neutral on Range Resources, Raises Price Target to $40

Piper Sandler analyst Mark Lear maintains Prairie Operating (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROP#NASDAQ">PROP</a>) with a Overweight and lowers the price target from $11 to $10.

PROP

Piper Sandler Maintains Overweight on Prairie Operating, Lowers Price Target to $10

UBS analyst Jon Windham maintains Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with a Neutral and raises the price target from $4.5 to $6.

FLNC

UBS Maintains Neutral on Fluence Energy, Raises Price Target to $6

Piper Sandler analyst Mark Lear maintains Permian Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>) with a Overweight and lowers the price target from $20 to $19.

Piper Sandler Maintains Overweight on Permian Resources, Lowers Price Target to $19

Macro Economic Events

WIIM

Economics

Major indexes are higher following softer-than-expected April inflation readings. Additionally, investors continue to weigh US-China trade progress and President Trump's Middle East trip.

SPDR Dow Jones Industrial Average ETF Trust

The Dow is lower amid weakness in one of its largest components, UnitedHealth, which fell after announcing a CEO change and suspending guidance.

Piper Sandler analyst Mark Lear maintains Northern Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) with a Neutral and lowers the price target from $34 to $30.

Piper Sandler Maintains Neutral on Northern Oil & Gas, Lowers Price Target to $30

UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>) with a Neutral and lowers the price target from $6 to $5.25.

GDRX

UBS Maintains Neutral on GoodRx Holdings, Lowers Price Target to $5.25

Piper Sandler analyst Mark Lear maintains Murphy Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) with a Overweight and lowers the price target from $35 to $30.

Piper Sandler Maintains Overweight on Murphy Oil, Lowers Price Target to $30

Piper Sandler analyst Mark Lear maintains Magnolia Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGY#NYSE">MGY</a>) with a Neutral and lowers the price target from $25 to $24.

Piper Sandler Maintains Neutral on Magnolia Oil & Gas, Lowers Price Target to $24

VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) reported quarterly earnings of $54.74 per share. This is a 72.67 percent decrease over earnings of $200.28 per share from the same period last year. The company reported $27.82 million in sales this quarter. This is a 40.64 percent increase over sales of $19.79 million the same period last year.

Earnings

VCIG

VCI Global FY EPS $54.74 Down From $200.28 YoY, Sales $27.82M Up From $19.79M YoY

Piper Sandler analyst Mark Lear maintains Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) with a Overweight and lowers the price target from $234 to $225.

FANG

Piper Sandler Maintains Overweight on Diamondback Energy, Lowers Price Target to $225

NuScale Power Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) shares surged 21.4% to $21.60 on Tuesday following the <a href="https://www.benzinga.com/pressreleases/25/05/b45359929/nuscale-power-reports-first-quarter-2025-results">release</a> of its first-quarter earnings after Monday&#8217;s close.
What To Know: The company <a href="https://www.benzinga.com/news/earnings/25/05/45361335/nuscale-power-reports-q1-results-details">reported</a> quarterly revenue of $13.4 million, significantly surpassing analysts&#8217; expectations of $4.26 million. The revenue boost was attributed to progress on its FEED Phase 2 project and a Technology License Agreement for Romania's RoPower Doicești power plant.
NuScale reduced its quarterly operating expenses by $2.3 million year-over-year to $42.3 million, largely due to lower R&amp;D costs as the company advances from development toward commercialization. The company&#8217;s net loss from operations narrowed to $35.3 million from $44.0 million in the same quarter last year.
Read Also: <a href="https://www.benzinga.com/news/25/05/45380609/applovin-stock-surges-on-strong-q1-earnings-and-tariff-truce-tailwinds">AppLovin Stock Surges On Strong Q1 Earnings And Tariff Truce Tailwinds</a>
CEO John Hopkins <a href="https://www.benzinga.com/news/earnings/25/05/45361335/nuscale-power-reports-q1-results-details">emphasized</a> NuScale's ongoing momentum as the only SMR provider with US NRC design approval. He noted that 12 reactor modules are already in production, with a target delivery date set for 2030.
NuScale, along with partner ENTRA1 Energy, is in advanced discussions with a range of potential customers, including governments, data centers and energy firms. 
The company ended the quarter with $521.4 million in liquidity and raised $102.4 million through its ATM equity program, reinforcing its capital position as it scales operations.
Read Also: <a href="https://www.benzinga.com/25/05/45378427/trump-wants-to-kickstart-nuclear-development-these-5-stocks-could-boom">Trump Wants To Kickstart Nuclear Development: These 5 Stocks Could Boom</a>
<h2 class="wp-block-heading">How To Buy SMR Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in NuScale Power&#8217;s case, it is in the Industrials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SMR has a 52-week high of $32.30 and a 52-week low of $5.86.

NuScale (SMR) Stock Surges 21% After Smashing Q1 Revenue Estimates

TD Cowen analyst Joseph Thome initiates coverage on Bright Minds Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>) with a Buy rating.

Initiation

DRUG

TD Cowen Initiates Coverage On Bright Minds Biosciences with Buy Rating

Piper Sandler analyst Mark Lear maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Neutral and raises the price target from $35 to $48.

Piper Sandler Maintains Neutral on EQT, Raises Price Target to $48

Western Digital shares are trading higher after the company announced a $2 billion buyback program.

Piper Sandler analyst Mark Lear maintains Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) with a Overweight and lowers the price target from $56 to $53.

Piper Sandler Maintains Overweight on Devon Energy, Lowers Price Target to $53

HOOD

Robinhood shares are trading higher after the company announced a deal to acquire WonderFi.

Press Releases

Tenon Medical(R) to Host Meetings During the 2025 J.P. Morgan Healthcare Conference in San Francisco

Tenon Medical, Inc. Announces Timing of Fourth Quarter and Full Year 2024 Financial Results

Tenon Medical(R) Receives Approval for Notice of Allowance from the European Patent Office

Tenon Medical, Inc. Announces a Warrant Inducement Transaction for $3.0 Million in Gross Proceeds

Tenon Medical Reports Fourth Quarter and Full Year 2024 Financial Results

Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion

Tenon Medical, Inc. Announces a Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Breakthroughs and Discoveries: TNON, PNPN.V, POAI, DYAI, PRSO, Drive Innovation Across Sectors

Tenon Medical, Inc. Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Comments

Tenon Medical

Tenon Medical (TNON) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL